Suppr超能文献

促卵泡激素受体基因中的常见 Asn680Ser 多态性与接受体外受精治疗患者的卵巢对促性腺激素刺激的反应无关。

A common Asn680Ser polymorphism in the follicle-stimulating hormone receptor gene is not associated with ovarian response to gonadotropin stimulation in patients undergoing in vitro fertilization.

机构信息

Department of Reproductive Medicine, St. Mary's Hospital, University of Manchester, Manchester, United Kingdom.

Genetic Medicine, Manchester Academic Health Sciences Centre (MAHSC), St. Mary's Hospital, University of Manchester, Manchester, United Kingdom.

出版信息

Fertil Steril. 2013 Jan;99(1):149-155. doi: 10.1016/j.fertnstert.2012.08.037. Epub 2012 Sep 15.

Abstract

OBJECTIVE

To assess the role of the variant p.Asn680Ser in the follicle-stimulating hormone receptor (FSHR) gene in determining ovarian response in patients undergoing in vitro fertilization (IVF) treatment.

DESIGN

Prospective observational study.

SETTING

Tertiary referral center for reproductive medicine.

PATIENT(S): Women (n = 421) undergoing their first cycle of controlled ovarian stimulation for IVF and 83 healthy, ethnically matched controls.

INTERVENTION(S): Baseline pelvic ultrasound and blood tests taken on days 2 to 3 of the cycle for assessment of baseline hormones and for DNA extraction.

MAIN OUTCOME MEASURE(S): Genotypes for FSHR p.Asn680Ser determined using TaqMan allelic discrimination assay, and ovarian response to gonadotropin treatment classified as normal, poor, or overresponse based on the number of oocytes retrieved.

RESULT(S): The FSHR p.Asn680Ser genotype frequencies were similar in IVF patients and controls. The number of oocytes retrieved was comparable between patients with different FSHR receptor genotypes. The total amount of gonadotropin used was also similar in all the genotype groups. A logistic regression analysis showed nonstatistically significant twofold difference in the distribution of genotypes between the groups with poor and normal ovarian response.

CONCLUSION(S): The variant FSHR p.Asn680Ser was not shown to be predictive of ovarian response, but clinically relevant differences cannot be ruled out.

摘要

目的

评估卵泡刺激素受体(FSHR)基因中变体 p.Asn680Ser 在决定接受体外受精(IVF)治疗的患者卵巢反应中的作用。

设计

前瞻性观察研究。

地点

生殖医学的三级转诊中心。

患者(n=421):接受他们的第一次控制性卵巢刺激周期的 IVF 治疗的女性和 83 名健康、种族匹配的对照者。

干预措施

在周期的第 2 至 3 天进行基础盆腔超声和血液检查,以评估基础激素水平,并提取 DNA。

主要观察指标

使用 TaqMan 等位基因鉴别检测确定 FSHR p.Asn680Ser 基因型,并根据获得的卵母细胞数量将卵巢对促性腺激素治疗的反应分类为正常、差或过度反应。

结果

IVF 患者和对照组的 FSHR p.Asn680Ser 基因型频率相似。具有不同 FSHR 受体基因型的患者获得的卵母细胞数量相似。所有基因型组的促性腺激素总用量也相似。逻辑回归分析显示,在卵巢反应差和正常的组之间,基因型的分布存在非统计学意义的两倍差异。

结论

变体 FSHR p.Asn680Ser 不能预测卵巢反应,但不能排除临床相关的差异。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验